Gleave ME - Search Results

1

The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.

Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. Jackson JK, et al. Among authors: gleave me. Cancer Res. 2000 Aug 1;60(15):4146-51. Cancer Res. 2000. PMID: 10945622

2

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Gleave ME, et al. Cancer Res. 1992 Mar 15;52(6):1598-605. Cancer Res. 1992. PMID: 1371718

3

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Gleave M, et al. Cancer Res. 1991 Jul 15;51(14):3753-61. Cancer Res. 1991. PMID: 1712249

4

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

5

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

6

Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.

Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW. Hsieh JT, et al. Among authors: gleave me. Cancer Res. 1993 Jun 15;53(12):2852-7. Cancer Res. 1993. PMID: 7684949

7

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD. Gleave ME, et al. Urology. 1996 May;47(5):708-12. doi: 10.1016/s0090-4295(96)80016-1. Urology. 1996. PMID: 8650870

8

Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.

Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Rabbani F, et al. Among authors: gleave me. Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394

9

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

10

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

667 results

Search Page

Filters